- Home
- BEST vs OTLK Comparison
BEST vs OTLK Comparison
Compare BEST & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEST
- OTLK
- Stock Information
- Founded
- BEST 2007
- OTLK 2010
- Country
- BEST China
- OTLK United States
- Employees
- BEST N/A
- OTLK N/A
- Industry
- BEST
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BEST
- OTLK Health Care
- Exchange
- BEST Nasdaq
- OTLK Nasdaq
- Market Cap
- BEST 55.9M
- OTLK 56.3M
- IPO Year
- BEST N/A
- OTLK 2016
- Fundamental
- Price
- BEST $2.78
- OTLK $1.56
- Analyst Decision
- BEST
- OTLK Strong Buy
- Analyst Count
- BEST 0
- OTLK 5
- Target Price
- BEST N/A
- OTLK $12.00
- AVG Volume (30 Days)
- BEST 33.2K
- OTLK 650.7K
- Earning Date
- BEST 03-26-2025
- OTLK 02-14-2025
- Dividend Yield
- BEST N/A
- OTLK N/A
- EPS Growth
- BEST N/A
- OTLK N/A
- EPS
- BEST N/A
- OTLK N/A
- Revenue
- BEST $1,183,106,017.00
- OTLK N/A
- Revenue This Year
- BEST N/A
- OTLK N/A
- Revenue Next Year
- BEST N/A
- OTLK $396.84
- P/E Ratio
- BEST N/A
- OTLK N/A
- Revenue Growth
- BEST 11.57
- OTLK N/A
- 52 Week Low
- BEST $1.85
- OTLK $0.87
- 52 Week High
- BEST $2.81
- OTLK $12.85
- Technical
- Relative Strength Index (RSI)
- BEST 73.75
- OTLK 34.22
- Support Level
- BEST $2.76
- OTLK $1.58
- Resistance Level
- BEST $2.81
- OTLK $1.99
- Average True Range (ATR)
- BEST 0.03
- OTLK 0.15
- MACD
- BEST 0.00
- OTLK -0.00
- Stochastic Oscillator
- BEST 69.31
- OTLK 6.52
About BEST BEST Inc. each representing twenty (20)
BEST Inc is a supply chain company. It provides a New Retail platform that offers technology-enabled integrated solutions such as supply chain management, express delivery, freight, merchandise sourcing, cross-border supply chain, last-mile, financial and value-added services. The Group operates in the following operating segments, Supply chain management services, Freight, Global and Others. The Others category principally relates to cross-border logistic coordination services. The majority of revenue generated from Freight segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.